Home » Market News » DirectorsTalk Highlights » Alastair Smith provides update on TMAC programme
Avacta Group Plc

Alastair Smith provides update on TMAC programme

In this short video, Avacta’s Chief Executive Officer Alastair Smith explains the TMAC® drug conjugate and the recent data from the lead molecule in that programme.

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.